BAY 79-4980 is a unique combination of recombinant factor VIII (rFVIII) with Zilip Pharma's proprietary synthetic polyethylene glycol (PEG)-coated liposomes. Although liposomes have been used successfully as a carrier to enhance the efficacy of other therapeutic agents in humans, the unique binding modality of BAY 79-4980 allows it to retain the full bioavailability and clotting factor properties of factor VIII, while extending activity at the same time.
The safety and pharmacokinetic profile of BAY 79-4980 were comparable to that of Kogenate® FS, a recombinant antihemophilic factor.
Source: Bayer Healthcare Press Release
.jpg)
Comment Preview